The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled.
Estimating the typhoid fever incidence is challenging in lowand middle-income countries, due to the non-specific clinical disease presentation and limited access to blood cultures, the most reliable laboratory diagnostic. The recent Typhoid Fever Surveillance in Africa Program measured the incidence of invasive Salmonella bloodstream infections in 10 African countries over a 27-month period [1] and demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates [2] . Importantly, 47% of Salmonella enterica serovar Typhi isolates were multidrug resistant. Similar studies have documented a significant burden of typhoid fever in sub-Saharan Africa [3] [4] [5] [6] . In Burkina Faso, the adjusted incidence of S. Typhi ranged from 104 to 383 per 100 000 person-years of observation (PYO) for all ages across 2 study sites. The highest adjusted incidence occurred in children 5-14 years of age at Nioko II (315 per 100 000 PYO) and in children 2-4 years of age at Polesgo (1890 per 100 000 PYO) [1] .
In addition to clean water and adequate sanitation, the World Health Organization (WHO) recommends vaccination against typhoid fever as an effective preventive measure. Before 2017, only 2 typhoid vaccines were available [7] : (1) the oral, live-attenuated Ty21a vaccine, licensed for children ≥6 years of age, and (2) an injectable Vi capsular polysaccharide vaccine, licensed for children ≥2 years of age. Recently, Bharat Biotech International developed a conjugate vaccine (Typbar-TCV) with Vi polysaccharide conjugated to a nontoxic tetanus toxoid (TT) protein carrier. This Vi-typhoid conjugate vaccine (Vi-TCV) stimulates both a strong, T-cell-dependent response and a more robust, anti-Vi response as compared to an unconjugated Vi polysaccharide vaccine. Vi-TCV safety and immunogenicity have been studied in adults and children as young as 6 months of age in India [8] , where a single dose elicited 4-fold seroconversion rates of 98% and 99% in participants 6-23 months and 2-15 years, respectively [8] . This vaccine holds significant promise, because of its single-dose schedule and utility in infants as young as 6 months of age.
While Vi-TCVs have been extensively studied in Asia, an ongoing clinical trial of Typbar-TCV in Malawian infants and children is the first-ever trial of any Vi-TCV in Africa [9] . This study will provide valuable data to sub-Saharan African decision-makers. However, because Expanded Program on Immunization (EPI) schedules differ throughout the continent, the WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-TCV with routine childhood vaccines in typhoid-endemic countries.
Available data from Asia on Typbar-TCV co-administration with measles-containing vaccines shows no altered immune response to either product; this result is being confirmed in Malawi in an immunogenicity sub-study of measles-rubella vaccine (MR) co-administration with Typbar-TCV [9] . Co-administration studies with yellow fever vaccine (YFV) and meningococcal A conjugate vaccine (MCV-A) are needed. Burkina Faso is the ideal study site, given its elevated burden of typhoid fever, elevated infant mortality, high malaria prevalence, ongoing typhoid surveillance, existing research infrastructure, and history of early introduction of WHO pre-qualified vaccines. The Burkina Faso immunization schedule includes YFV at 9 months and MCV-A at 15 months, in addition to MR at both 9 and 15 months.
TRIAL OVERVIEW
A randomized, controlled, Phase II trial will test Vi-TCV co-administration with vaccinations routinely given at 9 and 15 months of age in Burkina Faso. Our aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with vaccinations routinely given to children at both 9 and 15 months of age in Burkina Faso. The Vi-TCV vaccine or an inactivated poliovirus vaccine (IPV) will be administered. Children 9-11 months of age will be randomized 1:1 to Vi-TCV or IPV; children 15-23 months of age will be randomized 1:1:1 to Vi-TCV + MCV-A, Vi-TCV + IPV with delayed MCV-A, or MCV-A + IPV. We will use block randomization with varying block sizes from 6-12. Our study objectives and endpoints are listed in Table 1 .
Following the routine vaccination schedule, the vaccines will be administered to all participants per Burkina Faso Ministry of Health guidelines, except for 1 group of 50 children aged 15-23 months of age, who will delay MCV-A by 1 month. We anticipate recruiting 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) at a study site in Ouagadougou, Burkina Faso. The study duration (recruitment and follow-up) will be approximately 9 months. A trial schedule of events is found in Table 4 .
This study is sponsored by the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore, Maryland.
METHODS
This study will be divided into 2 cohorts, by age, with separate study designs. Cohort 1 will include children 9-11 months of age. Cohort 2 will include children 15-23 months of age. The purpose for our detailed evaluation of safety and immunogenicity is to assess vaccine reactogenicity and the immune response to Vi-TCV and co-administered vaccines. Serum will be collected from all participants on Day 0 (before vaccination) and on post-vaccination Day 28 to quantify anti-Vi and anti-TT antibodies. All children will have an additional 0.5 mL of blood collected on Day 0, before the study vaccination, to test for the presence of malaria parasitemia at baseline. Some studies demonstrate impaired immunogenicity of routine vaccinations in children with Plasmodium falciparum malaria at sites similar to Ouagadougou [10] [11] [12] , and we will evaluate this potential effect by measuring for P. falciparum parasitemia on Day 0. Children 9-11 months of age will be eligible for Cohort 1, a double-blind, individually randomized, controlled trial. Up to 100 children will be randomized in a 1:1 ratio to receive Vi-TCV (Group 1) or IPV (Group 2). Participants and parents will not know the study vaccine received. Vi-TCV or IPV will be administered with MR and YFV, as per Burkina Faso's EPI schedule. These 9-11-month-old children will have immunogenicity to Vi-TCV, YFV, and TT assessed on Days 0 and 28.
Children 15-23 months of age will be eligible for Cohort 2, a randomized safety and immunogenicity study of (1) Vi-TCV when co-administered with routine EPI vaccines (MCV-A and MR) or given alone and (2) MCV-A when co-administered or given alone. Participants in this cohort (up to 150) will be randomized 1:1:1: Group 3 participants will receive Vi-TCV and IPV at Day 0, with a subsequent dose of MCV-A at Day 28; Group 4 will receive MCV-A and Vi-TCV at Day 0; and Group 5 will receive MCV-A and IPV at Day 0. All children will receive MR at Day 0. Cohort 2 will be unblinded on Day 28 for safety and follow-up and to ensure MCV-A receipt in Group 3. These 15-23-month-old children will have serum bactericidal antibodies to Neisseria meningitidis serogroup A, anti-Vi antibody, and TT antibody assessed on Days 0 and 28.
We will measure anti-Vi immunoglobulin G (IgG) antibody responses using the VaccZyme Salmonella typhi Vi IgG enzymelinked immunosorbent assay commercial kit (The Binding Site Group Ltd, Birmingham, UK). Antibody titers will be expressed as enzyme-linked immunosorbent assay units per milliliter (U/mL). Both anti-Vi IgG antibody geometric mean titers and seroconversion, defined as a 4-fold or greater rise in anti-Vi antibody titers from baseline, will be calculated per group. The difference in geometric mean titers between the 2 groups will be compared using a 2-sample Student t test on log-transformed titers or a Mann-Whitney U test, as appropriate. The difference in the percentages of participants who seroconverted between the 2 groups will be compared using the Pearson's chi-square test or Fisher's exact test, as appropriate.
Participants in both cohorts will have home or clinic visits on Days 3 and 7 following vaccination, for local and systemic adverse event (AE) capture. Non-serious AEs will be assessed up to Day 28. Serious adverse events (SAEs) will be captured throughout the study follow-up.
Vi-Typhoid Conjugate Vaccine Dose
Typbar-TCV is a Vi-TCV vaccine manufactured by Bharat Biotech International (Hyderabad, India) that consists of 25 μg of Vi polysaccharide conjugated to a nontoxic tetanus toxoid protein carrier. It is given as a 0.5 ml dose by the intramuscular route to infants, toddlers, children, and adults. This vaccine will be shipped from the manufacturer in 5-dose, 2.5 mL vials.
Inactivated Poliovirus Vaccine Dose
The control vaccine for this study is Inactivated Poliovirus Vaccine (IMOVAX POLIO, Sanofi Pasteur, Lyon, France). This vaccine consists of 40 D-antigen units (DU) of Poliovirus type 1, 8 DU of Poliovirus type 2, and 32 DU of Poliovirus type 3 preserved in 2-phenoxyethanol (5 mg/mL). IPV is given as a 0.5 ml dose by the intramuscular route to infants, toddlers, children, and adults.
Study Population
Children aged 9-11 months and 15-23 months may enroll, provided they fulfill all inclusion and exclusion criteria (Table 2) and that their parent/guardian completes the informed consent process. The study recruits participants from Schiphra Medical Center in Ouagadougou, Burkina Faso.
STUDY PROCEDURES

Recruitment and Screening
Following community sensitization using Institutional Review Board (IRB)-approved materials, local community families with children aged 9-11 months and 15-23 months will be given study information in French and/or a local language (including Mossi, Dyula, and Fulani), either individually or in a group setting. The voluntary nature of the study and the right to withdraw will be explained. Parents of eligible children will then be encouraged to ask questions and will provide written informed consent in a semi-private area before enrollment and vaccination. The consent form will have a signature or thumbprint from the child's parent/ guardian before any study procedure. The adult literacy rate in Burkina Faso was 35% in 2014 [13] , and providing a thumbprint is a locally acceptable equivalent for a written signature. A copy will be given to the parent/guardian and another copy will be filed on site. If a parent/guardian is unable to read or sign, an impartial witness will document that all information was provided and consent was freely given. After informed consent is obtained, each potential participant will be screened for eligibility, according to the inclusion/exclusion criteria.
Randomization
Randomization will be computer-generated to allocate eligible participants in a 1:1 ratio for the 9-11-month-old cohort or a 1:1:1 ratio for the 15-23-month-old cohort, using stratified block randomization with varying block sizes from 6-12.
Blinding
Vi-TCV and IPV have similar pharmaceutical presentations. Unblinded study personnel will be responsible for vaccine preparation and administration. These unblinded personnel will not be involved in study-related assessments or have contact with subjects for the purpose of data collection following the study vaccination. Study participants, their family members, and study staff will not know the assigned vaccine group. The 15-23-month-old cohort will be unblinded on Day 28, so that Group 3 can receive MCV-A at this visit.
Enrollment
Screening and enrollment visits may occur on the same day. Study staff will review the participant's eligibility criteria, medical history, concomitant medications, and vaccination history. All participants will have their temperature taken and 3-5 mL of blood drawn for baseline immunogenicity and P. falciparum malaria parasitemia testing. Participants will be administered both the study and routine vaccinations (Figure 1) , then asked to remain in the study area for at least 30 minutes in case of a serious reaction. Any immediate reactions will be assessed and recorded.
Follow-up
Follow-up visits may be either routine or unscheduled. Routine visits will occur on Days 3, 7, 28, and 180. On Days 3 and 7 following vaccination, participants will be asked to return to the study clinic to assess reactogenicity. During these visits, solicited and unsolicited AEs will be recorded. Alternatively, these visits may be conducted in the home. On Day 28 following vaccination, participants will be asked to return to the study clinic for a follow-up visit. During this visit, the treatment groups in the 15-23-month-old cohort will be unblinded, participants will have approximately 3-5 mL of blood drawn to measure the Vi antibody responses for typhoid (all age groups), measure the TT serum IgG antibody levels (all age groups), and conduct the yellow fever plaque reduction neutralization testing (9-11-month-old group only) or measure the meningococcal A serum bactericidal antibody titers (15-23-month-old group only), which will be used for the primary and secondary objectives, as listed. Participants will have their final visit on Day 180, when interim SAEs will be recorded.
During unscheduled visits, participants will undergo standard procedures for the evaluation and treatment of illness, as defined by the Ministry of Health. Illnesses and other medical issues will be documented as AEs in participant records, and their seriousness, severity, relationship to the study product, and expectedness will be recorded.
ADVERSE EVENTS
Immediate Reactions
All participants will be observed for immediate reactions for 30 minutes after vaccination. Immediate reactions will be assessed by a study physician or appropriately trained medical staff member, and recorded on the appropriate case report form (CRF).
Solicited Local and Systemic Reactions
On Day 3, participants will be assessed for local and systemic reactions and will be asked about any events after vaccination on Day 0 and any current symptoms; on Day 7, participants will be assessed for local and systemic reactions and will be asked about current symptoms. Using a standardized data collection instrument, the following local and systemic reactions will be documented and graded on predefined scales, based on a functional assessment or the magnitude of the reaction: fever, injection site pain/tenderness, swelling, erythema, and irritability.
Note on Timing
All solicited and unsolicited AEs occurring through Day 7 post-vaccination will be assessed and recorded. All AEs that 
Study Inclusion and Exclusion Criteria
Inclusion Criteria 1. A healthy male or female child, either between the ages of 9-11 months or 15-23 months at the time of study vaccination. 2. A child whose parent/guardian resides primarily within the Ouagadougou study area at the time of study vaccinations and who intends to be present in the area for the duration of the trial. 3. A child whose parent/guardian has voluntarily given informed consent.
Exclusion Criteria
1. A history of documented hypersensitivity to any vaccine component. 2. Prior receipt of any typhoid vaccine. 3. For children 9-11 months, prior receipt of yellow fever vaccine or any measles-rubella-containing vaccine. 4. For children 15-23 months, prior receipt of meningococcal A conjugate vaccine or a second measles-rubella vaccine. 5. Prior receipt of any measles-rubella-containing vaccine (for children 9-11 months). 6. A history of severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis. 7. A known history of diabetes, tuberculosis, cancer, chronic kidney disease, heart disease, liver disease, a progressive neurological disorder, poorly controlled seizures, or a terminal illness. 8. Severe malnutrition, as determined by mid-upper arm circumference (MUAC) < 12.5 cm. 9. Receipt of any other investigational intervention in the last 6 months or anticipated receipt during the course of the study. 10. Receipt of blood products in the last 6 months. 11. A known human immunodeficiency virus infection or exposure, or other immunosuppressive conditions. 12. Receipt of systemic immunosuppressant or systemic corticosteroids. 13. Any condition determined by the investigator to be likely to interfere with evaluation of the vaccine, to be a significant potential health risk to the child, or to make it unlikely that the child would complete the study.
meet the criteria for an SAE and that occur through 6 months post-vaccination will be assessed and recorded.
Definition of Adverse Event
An AE is any untoward medical occurrence in a participant to whom Vi-TCV or IPV has been administered, including occurrences that are and are not caused by or related to the vaccine. All AEs related to study vaccination that are reported by telephone or by home or clinic visits in the first 7 days after vaccination will be recorded, including the event description, the date of onset, the resolution, the level of severity, an assessment of relatedness to the study, and the outcome.
Seriousness of Event
An untoward medical occurrence that meets any one of the following criteria is considered serious: results in death; is life-threatening; requires inpatient hospitalization or a prolongation of an existing hospitalization; or results in a persistent or significant disability. Other important medical events may be considered serious if the event jeopardizes the participant or requires intervention to prevent 1 of the above consequences.
Protocol Deviations
Protocol deviations will be collected in a CRF and kept in the study record. Deviations that affect the study's scientific integrity or a volunteer's rights/safety will be reported to the University of Maryland and local IRBs.
Analysis
Study hypotheses and power analyses are found in Table 3 . The intention-to-treat population includes all randomized individuals, in the vaccine groups to which they were assigned, and all follow-up time, beginning with the time of randomization. The primary analysis will be based on this population. The per-protocol population includes all vaccinated individuals, in the vaccine groups based on the vaccines they received. Additional details of study analyses will be included in a statistical analysis plan, which will be written by the study biostatistician before the study's data analysis begins.
Ethical Considerations
The study will be conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the principles of good clinical practice. The protocol and informed consent will be submitted to the University of Maryland IRB, the Regulatory Authority of the Ministry of Health of Burkina Faso, and the Ethics Committee for Health Research in Burkina Faso for written approval. Reports will be provided to the University of Maryland IRB and other parties annually. To compensate for their time and travel related to study activities, the participant's parent/guardian will receive $15 (7500 Franc Communauté Financière Africaine) for every scheduled clinic visit.
To protect participant confidentiality, study records will be stored in a locked office or in a password-protected, secure database. No information concerning the study or the data will be released to any unauthorized third party.
Potential Risks of Vi-Typhoid Conjugate Vaccine
In clinical trials among Indian children [8] , adverse reactions were predominantly minor and transient. Local reactions, such as injection site pain, erythema, and induration, usually resolved within 48 hours of vaccination. Fevers ≥38°C have been observed in approximately 1-4% of vaccinees [15] . A post-licensure study of Vi-TCV co-administration with a measles-rubella-containing vaccine was conducted, as was a Phase IV comparator study with the WHO pre-qualified Vi-polysaccharide vaccine. In both studies, no safety signals were reported and the Vi-TCV safety profile was comparable to the respective comparator. Post-marketing surveillance of Vi-TCV, based on approximately 3000 reports, has shown fever, pain, and swelling around the injection site to occur in 1-10% of vaccinees in any age group, with no SAEs reported [16] . The WHO's Global Advisory Committee on Vaccine Safety review found no safety signal related to the vaccine [16] .
Potential Risks of Inactivated Poliovirus Vaccine
The most common reactions following the receipt of an IPV are local injection site reactions (eg, pain, erythema, and Reactogenicity following Vi-TCV given together with YFV and MR (Group 1) is not significantly different from reactogenicity following IPV given together with YFV and MR (Group 2).
The expected incidence of any grade 2 or greater solicited, systemic adverse events over 7 days following vaccination is 10% in Group 2 [14] . Sample sizes of 45 in Group 1 and 45 in Group 2 achieve 80% power to detect a minimum difference of 0.23 (= 33% -10%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15).
The percentage of participants with seroconversion (≥2-fold rise) in yellow fever neutralizing antibodies following a single dose of Vi-TCV given together with YFV and MR (Group 1) is not significantly different from the percentage of participants with seroconversion (≥2-fold rise) in yellow fever neutralizing antibodies following a single dose of IPV given together with YF and MR (Group 2).
In Group 2, the expected seroconversion proportion is 70% [14] . Sample sizes of 45 in Group 1 and 45 in Group 2 achieve 80% power to detect a minimum difference of 0.28 (= 70% -42%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15). Reactogenicity following a single dose of Vi-TCV given together with IPV and MR (Group 3) is not significantly different from reactogenicity following a single dose of Vi-TCV given together with MCV-A and MR (Group 4).
The expected incidence of any grade 2 or greater solicited, systemic adverse events over 7 days following vaccination is 10% in Group 3 [14] . Sample sizes of 45 in Group 3 and 45 in Group 4 achieve 80% power to detect a minimum difference of 0.23 (= 33% -10%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15).
Reactogenicity following a single dose of Vi-TCV given together with MCV-A and MR (Group 4) is not significantly different from reactogenicity following a single dose of IPV given together with MCV-A and MR (Group 5).
The expected incidence of any grade 2 or greater solicited systemic adverse events over 7 days following vaccination is 10% in Group 5 [14] . Sample sizes of 45 in Group 4 and 45 in Group 5 achieve 80% power to detect a minimum difference of 0.23 (= 33% -10%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15). In Group 5, the expected seroconversion proportion is 90% [14] . Sample sizes of 45 in Group 4 and 45 in Group 5 achieve 80% power to detect a minimum difference of 0.23 (= 90% -67%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15).
The percentage of participants with seroconversion (≥4-fold rise) in Anti-Vi IgG antibodies following a single dose of Vi-TCV given together with IPV and MR (Group 3) is not significantly different from the percentage of participants with seroconversion (≥4-fold rise) in Anti-Vi IgG antibodies following a single dose of Vi-TCV given together with MCV-A and MR (Group 4).
In Group 3, the expected seroconversion proportion is 95% [8] .
Sample sizes of 45 in Group 3 and 45 in Group 4 achieve 80% power to detect a minimum difference of 0.20 (= 95% -75%), using a 2-sided z-test with unpooled variance and a significance level of 5% (PASS 15).
Abbreviations: IgG, immunoglobulin G; IPV, inactivated poliovirus vaccine; MCV-A, meningococcal A conjugate vaccine; MR, measles-rubella vaccine; Vi-TCV, Vi-typhoid conjugate vaccine; YFV, yellow fever vaccine.
induration) and moderate, transient fever. Other rare reactions (less than 0.01% of vaccine recipients) include edema, lymphadenopathy, transient arthralgia and myalgia, convulsions, headaches, paresthesia, somnolence, irritability, and allergic reactions (urticarial, facial edema, or anaphylactic shock) [17] .
Data
Research records will be stored in a locked room and on a secure electronic database, in compliance with International Conference for Harmonisation E6. Only authorized personnel will have access to these data. Regulatory agencies may examine the records for quality assurance reviews, audits, and the evaluation of the study's safety and progress. Safety and immunogenicity data will be recorded on paper CRFs for subsequent data entry or entered directly into an electronic database. Studyspecific CRFs will be generated.
Quality Control and Quality Assurance
The site developed a protocol-specific quality management plan in conjunction with the University of Maryland Center for Vaccine Development and Global Health Office of Regulatory Affairs and Quality Management. This plan details how data will be evaluated for protocol compliance, which documentation will be reviewed, and the methods for training staff.
Monitoring
The sponsor's team will visit the site before the study's start to discuss the protocol and data collection procedures with site personnel. Before participant enrollment, required regulatory documents must be available. Subsequent study monitoring will be conducted according to the sponsor's requirements. Study monitors will periodically review the progress and access all records necessary to ensure the ethical and safe study conduct and the integrity/validity of recorded data.
Plans for Dissemination of Results
The principal investigator and sponsor investigator will oversee the collection, approvals, and dissemination of study data. All publications and presentations will be reviewed by each co-investigator before submission. In accordance with the Bill & Melinda Gates Foundation policy, all study-related publications will be open access. Authorship will comply with International Committee of Medical Journal Editors guidelines. 
